Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222

Atherosclerosis

Volumn 227, Issue 1, 2013, Pages 65-71

  Kothapalli, Devashish ^a   Castagnino, Paola ^a   Rader, Daniel J ^a   Phillips, Michael C ^b   Lund Katz, Sissel ^b   Assoian, Richard K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Apo; ApoE3; Cdk; HDL; LDL; MiR221 222; P27; PGI2; QPCR; VSMC; VSMC proliferation

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E3; CYCLOOXYGENASE 2; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA 221; MICRORNA 222; PROSTACYCLIN; PROTEIN P27;

ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL STIMULATION; CONTROLLED STUDY; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOLIPOPROTEIN E3; CELL CYCLE CHECKPOINTS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLOOXYGENASE 2; MALE; MICE; MICRORNAS; MUSCLE, SMOOTH, VASCULAR;

EID: 84873424343     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.12.003     Document Type: Article

References (37)

1. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000, 1:507-537.
2. Ribalta J., Vallve J.C., Girona J., et al. Apolipoprotein and apolipoprotein receptor genes, blood lipids and disease. Curr Opin Clin Nutr Metab Care 2003, 6:177-187.
3. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994, 45:249-302.
4. Ishigami M., Swertfeger D.K., Granholm N.A., et al. Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase. J Biol Chem 1998, 273:20156-20161.
5. Ishigami M., Swertfeger D.K., Hui M.S., et al. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2000, 20:1020-1026.
6. Kothapalli D., Fuki I., Ali K., et al. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest 2004, 113:609-618.
7. Paka L., Goldberg I.J., Obunike J.C., et al. Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth?. J Biol Chem 1999, 274:36403-36408.
8. Swertfeger D.K., Hui D.Y. Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 2001, 276:25043-25048.
9. Zhu B., Kuhel D.G., Witte D.P., et al. Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice. Am J Pathol 2000, 157:1839-1848.
10. Weisgraber K.H., Mahley R.W. Human apolipoprotein E: the Alzheimer's disease connection. FASEB J 1996, 10:1485-1494.
11. Ali K., Lund-Katz S., Lawson J., et al. Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells. Atherosclerosis 2008, 196:201-209.
12. Marks A.R. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 2003, 349:1307-1309.
13. Marx S.O., Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001, 104:852-855.
14. Diez-Juan A., Andres V. The growth suppressor p27(Kip1) protects against diet-induced atherosclerosis. FASEB J 2001, 15:1989-1995.
15. Cheng Y., Austin S.C., Rocca B., et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002, 296:539-541.
16. Morrow J.A., Arnold K.S., Weisgraber K.H. Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. Protein Expr Purif 1999, 16:224-230.
17. Lund-Katz S., Zaiou M., Wehrli S., et al. Effects of lipid interaction on the lysine microenvironments in apolipoprotein E. J Biol Chem 2000, 275:34459-34464.
18. Hatch F.T. Practical methods for plasma lipoprotein analysis. Adv Lipid Res 1968, 6:1-68.
19. Weisgraber K.H., Mahley R.W. Subfractionation of human high density lipoproteins by heparin-sepharose affinity chromatography. J Lipid Res 1980, 21:316-325.
20. Welsh C.F., Roovers K., Villanueva J., et al. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 2001, 3:950-957.
21. Kothapalli D., Zhao L., Hawthorne E.A., et al. Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. J Cell Biol 2007, 176:535-544.
22. Kitajima K., Marchadier D.H., Miller G.C., et al. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 2006, 26:1852-1857.
23. Castagnino P., Kothapalli D., Hawthorne E.A., et al. Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost. Prostaglandins Other Lipid Mediat 2010, 93:20-24.
24. Carrano A.C., Eytan E., Hershko A., et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1:193-199.
25. DeSalle L.M., Pagano M. Regulation of the G1 to S transition by the ubiquitin pathway. FEBS Lett 2001, 490:179-189.
26. Malek N.P., Sundberg H., McGrew S., et al. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001, 413:323-327.
27. Kamura T., Hara T., Matsumoto M., et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27Kip1 at G1 phase. Nat Cell Biol 2004, 6:1229-1235.
28. Davis B.N., Hilyard A.C., Nguyen P.H., et al. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem 2009, 284:3728-3738.
29. le Sage C., Nagel R., Egan D.A., et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. Embo J 2007, 26:3699-3708.
30. Liu X., Cheng Y., Zhang S., et al. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 2009, 104:476-487.
31. Kothapalli D, Liu S-L, Bae Y-H, et al. Cardiovascular protection by apoE and apoE-HDL linked to suppression of ECM gene expression and arterial stiffening, Cell reports, , 2012. http://dx.doi.org/10.1016/j.celrep.2012.09.018.
32. Yung Y., Walker J.L., Roberts J.M., et al. A Skp2 autoinduction loop and restriction point control. J Cell Biol 2007, 178:741-747.
33. Zhang L., Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006, 25:2615-2627.
34. Cohn J.S., Tremblay M., Amiot M., et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1996, 16:149-159.
35. Zeleny M., Swertfeger D.K., Weisgraber K.H., et al. Distinct apolipoprotein E isoform preference for inhibition of smooth muscle cell migration and proliferation. Biochemistry 2002, 41:11820-11823.
36. Liu X., Cheng Y., Yang J., et al. Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. J Mol Cell Cardiol 2012, 52:245-255.
37. Rippe C., Blimline M., Magerko K.A., et al. MicroRNA changes in human arterial endothelial cells with senescence: relation to apoptosis, eNOS and inflammation. Exp Gerontol 2012, 47:45-51.